Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.

CONCLUSION: The duration of each previous PFS is a major prognostic factor for OS in mTNBC patients receiving third- or fourth-line chemotherapy. The clinical utility of nomograms including this information was not demonstrated. PMID: 33561617 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33561617?dopt=Abstract

Source: Breast - January 30, 2021 Category: Cancer & Oncology Authors: Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Tags: Breast Source Type: research